Literature DB >> 11972529

Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis.

Christine J Harrison1, Helen Mazzullo, Fiona M Ross, Kan L Cheung, Gareth Gerrard, Louise Harewood, Atul Mehta, Helen J Lachmann, Philip N Hawkins, Kim H Orchard.   

Abstract

Systemic monoclonal immunoglobulin light chain amyloidosis (AL) is associated with clonal plasma cell dyscrasias that are often subtle and non-proliferating. AL shares numerical chromosomal changes with multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS). Illegitimate translocations involving the immunoglobulin heavy chain gene (IGH) at 14q32 and deletions of the long arm of chromosome 13, [del(13q)], commonly occur in MM, MGUS and plasma cell leukaemia. In AL IGH rearrangements have been identified but, to date, there are no reports of del(13q). In this study of 32 patients with AL, 24 with systemic and eight with localized disease, translocations involving IGH and del(13q) were found using dual-colour interphase fluorescence in situ hybridization (FISH). IGH translocations were observed in 11 patients (37% overall and in 46% with systemic disease), of which nine had the IGH/CCND1 fusion from t(11;14)(q13;q32). Two showed IGH translocations other than the t(11;14) or t(4;14)(p16;q32). In one of these patients a breakpoint within the constant region of IGH between Calpha1 and Calpha2 was indicated. In the second a deletion covering Calpha1 and Calpha2 accompanied the translocation. Ten patients (27% overall and 33% of those with systemic disease) showed del(13q). The gain or loss of IGH and CCND1 signals provided evidence of numerical chromosomal changes in three patients.

Entities:  

Mesh:

Year:  2002        PMID: 11972529     DOI: 10.1046/j.1365-2141.2002.03438.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Dysregulation of miRNAs in AL amyloidosis.

Authors:  Liangping Weng; Brian H Spencer; Pamela T SoohHoo; Lawreen H Connors; Carl J O'Hara; David C Seldin
Journal:  Amyloid       Date:  2011-08-11       Impact factor: 7.141

Review 2.  Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Authors:  Adriana Zingone; W Michael Kuehl
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

3.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Ashraf H Ibrahim; Elizabet Dachs Cabanas; Rebecca K M Protheroe; David M Stockley; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

4.  Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.

Authors:  E Muchtar; A Dispenzieri; S K Kumar; R P Ketterling; D Dingli; M Q Lacy; F K Buadi; S R Hayman; P Kapoor; N Leung; R Chakraborty; W Gonsalves; R Warsame; T V Kourelis; S Russell; J A Lust; Y Lin; R S Go; S Zeldenrust; R A Kyle; S V Rajkumar; M A Gertz
Journal:  Leukemia       Date:  2016-12-01       Impact factor: 11.528

5.  Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

Authors:  M I da Silva Filho; A Försti; N Weinhold; I Meziane; C Campo; S Huhn; J Nickel; P Hoffmann; M M Nöthen; K-H Jöckel; S Landi; J S Mitchell; D Johnson; G J Morgan; R Houlston; H Goldschmidt; A Jauch; P Milani; G Merlini; D Rowcieno; P Hawkins; U Hegenbart; G Palladini; A Wechalekar; S O Schönland; K Hemminki
Journal:  Leukemia       Date:  2016-12-27       Impact factor: 11.528

6.  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Steven Zeldenrust; Shaji Kumar; Suzanne Hayman; Francis Buadi; Robert A Kyle; Philip R Greipp; John A Lust; Stephen Russell; S Vincent Rajkumar; Rafael Fonseca; Angela Dispenzieri
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

7.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

Authors:  Julie O'Neal; Feng Gao; Anjum Hassan; Ryan Monahan; Samantha Barrios; Manfred W Kilimann; Ian Lee; Wee J Chng; Ravi Vij; Michael H Tomasson
Journal:  Exp Hematol       Date:  2009-02       Impact factor: 3.084

8.  Cardiac amyloidosis masquerading as biventricular hypertrophy in a patient with multiple myeloma.

Authors:  Haseeb Ilias Basha; Ethiraj Raj; Ghassan Bachuwa
Journal:  BMJ Case Rep       Date:  2013-07-29

9.  A novel report of cig-FISH and cytogenetics in POEMS syndrome.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Shaji Kumar; Robert A Kyle; Rafael Fonseca; Phillip R Greipp; John A Lust; Vincent S Rajkumar; Suzanne R Hayman; Francis Buadi; Stephen J Russell; Stephen R Zeldenrust; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

Review 10.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.